• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Introduction to 4-Cyclohexyl-1H-imidazole hydrochloride (CAS No. 2680539-93-7)

4-Cyclohexyl-1H-imidazole hydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 2680539-93-7, is a significant compound in the realm of pharmaceutical and chemical research. This compound belongs to the imidazole class, which is well-documented for its diverse biological activities and applications in medicinal chemistry. The presence of a cyclohexyl group in its molecular structure introduces unique pharmacokinetic and pharmacodynamic properties, making it a subject of considerable interest in drug development.

The hydrochloride salt form of 4-cyclohexyl-1H-imidazole enhances its solubility in aqueous solutions, a crucial factor for formulation in pharmaceutical applications. This solubility profile is particularly advantageous for developing drug delivery systems that require precise control over bioavailability and therapeutic efficacy. The compound's stability under various conditions further adds to its appeal as a candidate for further investigation.

In recent years, there has been growing interest in imidazole derivatives due to their potential as scaffolds for novel therapeutic agents. The structural motif of imidazole, characterized by a five-membered ring containing two nitrogen atoms, is known to interact favorably with biological targets such as enzymes and receptors. The introduction of the cyclohexyl group in 4-cyclohexyl-1H-imidazole hydrochloride modifies these interactions, potentially leading to new mechanisms of action.

One of the most compelling areas of research involving 4-cyclohexyl-1H-imidazole hydrochloride is its application in the development of antimicrobial agents. The imidazole core has been shown to exhibit activity against a range of pathogens, including bacteria and fungi. Studies have demonstrated that modifications to the imidazole ring can enhance its antimicrobial properties without compromising safety profiles. The cyclohexyl substituent may contribute to improved binding affinity and selectivity, making this compound a promising candidate for further exploration.

Moreover, 4-cyclohexyl-1H-imidazole hydrochloride has shown potential in other therapeutic domains. For instance, researchers have investigated its role in modulating inflammatory responses and immune function. Imidazole derivatives are known to interact with various immunomodulatory pathways, and the structural features of 4-cyclohexyl-1H-imidazole hydrochloride may enable it to influence these pathways selectively. This has implications for the development of treatments for autoimmune diseases and chronic inflammatory conditions.

The synthesis of 4-cyclohexyl-1H-imidazole hydrochloride involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic methodologies, such as transition metal-catalyzed cross-coupling reactions, have been employed to enhance efficiency and minimize byproduct formation. These synthetic approaches are critical for producing sufficient quantities of the compound for preclinical and clinical studies.

Preclinical studies have provided valuable insights into the pharmacological properties of 4-cyclohexyl-1H-imidazole hydrochloride. These studies have focused on evaluating its efficacy, safety, and pharmacokinetic profile in animal models. Results from these studies suggest that the compound exhibits favorable properties that make it suitable for further development into a therapeutic agent. For example, preliminary data indicate that it may have a broad spectrum of activity against various pathogens while maintaining good tolerability.

The potential applications of 4-cyclohexyl-1H-imidazole hydrochloride extend beyond antimicrobial therapy. Researchers are exploring its utility in the treatment of neurological disorders, where imidazole derivatives have demonstrated neuroprotective effects. The cyclohexyl group may enhance blood-brain barrier penetration, allowing the compound to reach target sites more effectively. This opens up new avenues for treating conditions such as epilepsy and neurodegenerative diseases.

In conclusion, 4-Cyclohexyl-1H-imidazole hydrochloride (CAS No. 2680539-93-7) is a versatile compound with significant potential in pharmaceutical research. Its unique structural features and demonstrated biological activities make it an attractive candidate for developing novel therapeutic agents across multiple disease areas. As research continues to uncover new applications and refine synthetic methodologies, the future prospects for this compound appear promising.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)